Royalty Report: Drugs, Hair loss, Personal Care Products – Collection: 383570

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Hair loss
  • Personal Care Products
  • Pharmaceuticals
  • Psoriasis
  • Medical
  • Device
  • Supply
  • Disease
  • Therapeutic
  • Dermatology
  • Diagnostic
  • Molecular
  • Proteins
  • Skin care

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 383570

License Grant
The University grants to Licensee of Bermuda an exclusive, worldwide right and license, with the right to sublicense, under University Patent Rights to make, have made, use, sell, offer for sale and import Product in the Field of Use during the Term.
License Property
The University owns and controls certain innovative technology for regrowth of hair.

The patents are
— Prostaglandin D2 Synthase and its Products as Cause of Hair Loss and Target for Therapy;
— Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia.

Field of Use
The Field of Use means hair growth and hair removal in humans.

IPSCIO Record ID: 292798

License Grant
Licensor grants the Licensee of China a limited, exclusive, personal, non-assignable and non-sublicensable license in the Territory during the Term to import, test, use, have used, register and take such requisite actions with respect to the Product necessary to approve the Product for Commercialization in the Territory.

Licensor grants an exclusive, personal, non-assignable, non-sublicensable license during the Term, after approval of a Product for Commercialization within the Territory, to import, use, have used, sell, offer for sale, resell and distribute the Product solely in the Territory.

Licensor will be the exclusive supplier of Product to Licensee,

Licensor grants, during the Term, a license in the Territory on a limited, non-exclusive, personal, non-assignable, and non-sublicensable basis to the Licensor Trademarks.

License Property
Licensor Trademarks means the Trademark Histogen, and any other Trademarks of Licensor that the Post-Commercialization Joint Steering Committee determines are needed for the marketing, promotion and labeling of the Product within the Territory.

Product means a product supplied by Licensor to Licensee containing the Hair Stimulating Complex (HSC), which is a soluble formulation developed by Licensor as an injectable for hair regrowth,  comprises growth factors involved in hair viability such as keratinocyte growth factor (KGF), vascular endothelial growth factor (VEGF), and follistatin, and is produced by neonatal cells grown under simulated embryonic conditions of hypoxia (3-5% oxygen).

The patents include Extracellular Matrix Compositions, and, Conditioned Medium And Extracellular Matrix Compositions From Cells Cultured Under Hypoxic Conditions.

Field of Use
Technology relates to  Histogen’s hair growth product, called hair stimulating complex (HSC).  HSC is an injection treatment that has shown excellent safety and statistically and cosmetically significant hair growth in clinical trial.

Competing Product means with respect to the Parties,  any product incorporating keratinocyte growth factor (KGF), vascular endothelial growth factor (VEGF), and/or follistatin, other than the Products, or any other product incorporating any other hair growth factor, or a variety thereof, that directly competes against HSC or  with respect to an Acquirer, any product incorporating keratinocyte growth factor (KGF), vascular endothelial growth factor (VEGF), and/or follistatin.

IPSCIO Record ID: 28991

License Grant
Licensor grants an exclusive license for the Licensed Technology in the Field, including, without limitation, the patents and patent applications with the right to grant sublicenses, as well as the right of its sublicensees to grant further sublicenses, to make, have made, use, distribute and sell Licensed Products in the Field using the Licensed Technology covered by the Licensed Patent Rights throughout the Territory.
License Property
PTH technologies useful in the treatment of psoriasis and hair loss.

U.S. Patent No. 5,527,772, 5,840,690, 6,066,618

IPSCIO Record ID: 110284

License Grant
Pursuant to this Sale and Exclusive License/Supply Agreement, Licensee was granted a global exclusive license to devices and consumable products for hair applications.
License Property
Celution® devices and consumable products including all future generations, comparable derivatives, successors or alternative adipose derived regenerative cell devices (hereinafter referred to as the “Celution Products”) for the “Hair Field”.

Celution 800/CRS Device An automated, electromechanical device containing multilingual, interactive software that facilitates the extraction and concentration of ADRCs, using validated algorithms programmed into the device’s software, standardizing tissue disaggregation, centrifugation and therapeutic- specific processes.

Celution 805/CRS Consumable Set A sterile, single-use set used with the Celution Device to process tissue and extract ADRCs within a closed system.

Field of Use
Licensee’s focus is on the aesthetics cash-pay market and has systems for managing male and female pattern baldness such as The Kerastem Hair Therapy, a CE mark approved for patients with alopecia (hair loss) outside the United States.

IPSCIO Record ID: 109062

License Grant
The University assigned the patent for the Vitamin D3 technology to the Licensee to utilize.
License Property
The Vitamin D3 technology is U.S. Patent Number 5,486,509 – Method of preventing and treating chemotherapy-induced alopecia.
Field of Use
Hair loss (alopecia) associated with chemotherapy and other cancer treatments is one of the adverse effects most commonly associated with cancer treatment and may be an especially dreaded marker of status as a cancer patient.

IPSCIO Record ID: 279348

License Grant
Licensor grants
—  during the Research Term, a non-exclusive, worldwide, license, without the right to sublicense, under the Licensor Technology solely to perform Licensees obligations under the Research Plan; and
—  an exclusive, worldwide license, including the right to sublicense, under the Licensor Technology and Licensors interest in the Joint Patent Rights, to develop, make, have made, use, sell, have sold, offer for sale and import Selected Compounds and Products solely in the Licensee Field.
License Property
Licensor possesses scientific and proprietary technology and data and resources relating to the Hedgehog Pathway.  Hedgehog Pathway shall mean the biological signaling cascade which stimulates the transcription of various genes that mediate Hedgehog-dependent phenotypic cellular changes, as evidenced by the upregulation of transcription of Gli.

Product shall mean any final dosage form of a pharmaceutical product containing a Selected Compound for use in the Licensee Field.

Field of Use
Licensee possesses scientific and technical resources relating to the development and commercialization of pharmaceutical products for the treatment of skin diseases and/or disorders or for the promotion of hair growth in humans.

Licensor Field shall mean the local administration of Excluded Compounds for
—  the treatment or prevention of cardiovascular diseases and disorders in humans, including but not limited to the use of an Excluded Compound coated on a cardiovascular stent and ex vivo use of Excluded Compounds for the preparation of cells to be used in cell therapy applications; and/or any other indication in humans (excluding any indication within the Licensee Field) to which Licensor obtains rights from Third Party after the Effective Date; and/or
—  the Veterinary Field.  Veterinary Field shall mean Topical Application of a Licensed Compound for the treatment or prevention of any skin disease or disorder in animals, excluding humans.

Licensee Field shall mean the Topical Application of a Selected Compound or Product for the promotion of hair growth in humans (Hair Growth lndications); and/or any other indication in which Topical Application is used in humans – each, a Skin-Related Indication.

IPSCIO Record ID: 383569

License Grant
Licensor of Switzerland grants the Licensee of Bermuda and the United States an exclusive, even as to Licensor except to the extent necessary to fulfill its obligations under this Agreement, sublicensable, transferable license under the Licensed Patents to Research, Develop, make, have made, use, sell, offer for sale, import and otherwise Commercialize Compounds and/or Licensed Products in the Field in the Territory.

Licensor grants a non-exclusive, sublicensable, transferable license under the Licensed Know-How to Research, Develop, make, have made, use, sell, offer for sale, import and otherwise Commercialize Compounds and/or Licensed Products in the Field in the Territory.

Licensor grants a non-exclusive, sublicensable, transferable license under the FTO Patents to Research, Develop, make, have made, use, sell, offer for sale, import and otherwise Commercialize Compounds and/or Licensed Products in the Territory.

Licensor will use Commercially Reasonable Efforts to transfer to Licensee all items of  Licensed Know-How, including Manufacturing know-how.

For Research, Development, and Manufacturing of Licensed Products Scope & Diligence, Licensee will have sole control and responsibility for the Research, Development, Manufacture and Commercialization of all Licensed Products.

License Property
Licensor has discovered and developed small molecule antagonists to the target known as CRTH2, including the compound known as setipiprant.

Licensor FTO Patents mean any Patents that
— are not Licensor Licensed Patents or Licensor Related Patents;
— cover manufacturing processes, including intermediates, or formulations of Compounds or Licensed Products, or uses of Compounds or Licensed Products for hair growth or the prevention of hair loss; and
—  Licensor or its Affiliates Controls as of the Effective Date or during the Term.

Compounds means
— Licensors compound known as setipiprant ;
— all other compounds covered by the Patents listed; and
— the salts, enantiomers, racemates, polymorphs, crystalline forms, non-crystalline forms, hydrates, solvates, esters, conjugates, metabolites and prodrugs of the compounds.

CRTH2 means
— the gene encoding the chemoattractant receptor-homologous molecule expressed on Th2 cells for any species, which molecule is also known as GPR44 or DP2;
— the protein encoded by such gene; and
— all subtypes, mutants and variants thereof.

CRTH2 Antagonists means any molecule with a primary mechanism of action of antagonizing CRTH2.

Patents are titled/relate to Tetrahydropyridoindole derivatives.

Field of Use
IP is for a novel approach for the treatment of hair loss. Setipiprant is a selective oral antagonist to the prostaglandin D2 (PGD2) receptor. The elevation of PGD2 levels in certain regions of the male scalp is associated with hair loss in those regions.

IPSCIO Record ID: 320535

License Grant
The Licensor of England entered into a Royalty Agreement with the Licensee for the development and commercialization of the intellectual property licensed products using any mechanical, energy or chemical based approaches, applying compounds to the skin, or any other approaches to the treatment of dermatological disorders.
License Property
The  intellectual property licensed products are (i) products involving skin disruption using any mechanical, energy or chemical based approaches, applying compounds to the skin, or any other approaches to the treatment of hair follicles or other dermatological disorders commercialized by Licensee. (ii) processes involving such products, or (iii) services which use or incorporate any such product or process.
Field of Use
The field of use is for the treatment of hair follicles or other dermatological disorders.  The hair follicle is an organ found in mammalian skin. It resides in the dermal layer of the skin and is made up of 20 different cell types

Licensee is developing a regenerative biology platform designed to treat androgenetic alopecia, epithelial aging and other medical conditions for the treatment of hair loss in male androgenetic alopecia.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.